SH3PXD2B is an adapter protein that organizes invadopodia and podosome formation through its SH3 and PX domains. It functions as a scaffold that coordinates NADPH oxidase (NOX1/NOX3)-dependent reactive oxygen species (ROS) generation and localizes matrix metalloproteinases and phosphoinositide signaling to sites of extracellular matrix degradation 1. SH3PXD2B plays a crucial role in adipogenesis; knockdown studies demonstrate that SH3PXD2B is essential for proper adipocyte lipidation and differentiation, with loss-of-function reducing expression of key adipogenic regulators including DGAT2, LPL, ADIPOQ, PPARG, and SREBF1 2. Disease relevance is substantial. SH3PXD2B mutations cause Frank-Ter Haar syndrome, an autosomal-recessive disorder featuring skeletal abnormalities, cardiac defects, and ocular pathology 3, and contribute to a broader spectrum of collagen remodeling disorders alongside MMP14 and MMP2 mutations 1. Beyond rare genetic disease, SH3PXD2B is upregulated in multiple cancers. Elevated expression in hepatocellular carcinoma correlates with poor prognosis, advanced TNM stage, and enhanced invasion through invadopodia formation 4. Similarly, high SH3PXD2B expression in gastric cancer associates with poor prognosis and promotes cell proliferation and migration through immunosuppressive cell recruitment 5. SH3PXD2B has been identified in a novel fusion oncogene (SH3PXD2B::FER) in plexiform myofibroblastic tumor 6, suggesting broader oncogenic potential.